EMA Picks Antibiotic Combo & RSV Vaccine For New International Parallel Review Framework

 
• By Neena Brizmohun

The first products to be selected for review under the European Medicines Agency’s newly extended OPEN framework for collaboratively assessing marketing applications with non-EU authorities are from Pfizer/AbbVie and Moderna.

Brainstorming. Joint project. Development of innovations and technologies. Research. Cooperation
The EMA's OPEN framework enables international collaboration on marketing application reviews • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards